AlainAlgaziMD

Oncology • San Francisco, CA

Assistant Professor, Medicine, University of California, San Francisco, School of

Join to view full profile

Dr. Algazi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Algazi's full profile

Already have an account?

Office
505 Parnassus Ave # M1286
Box 1270
San Francisco, CA 94143
Phone+1 415-476-0624

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2007 - 2010
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2004 - 2007
David Geffen School of Medicine at UCLAClass of 2004

Certifications & Licensure

CA State Medical License 2006 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma Start of enrollment: 2012 Jun 09
Completed
Phase 1, Phase 2
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets Start of enrollment: 2013 Apr 01
Terminated
Phase 2
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Start of enrollment: 2013 May 01
Completed
Phase 2
Trametinib With GSK2141795 in BRAF Wild-type Melanoma Start of enrollment: 2013 Sep 10
Completed
Phase 2
Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
ACTIVE_NOT_RECRUITING
PHASE2
Trial of pIL-12/MK-3475 in Metastatic Melanoma Start of enrollment: 2015 Aug 17
Completed
Phase 2
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Start of enrollment: 2016 Jul 06
ACTIVE_NOT_RECRUITING
PHASE2
Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2019 Mar 08
RECRUITING
PHASE2
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09
COMPLETED
PHASE1, PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMa...
Raymond Y Huang, Gilbert Youssef, Thomas Nelson, Patrick Y Wen, Peter Forsyth
Journal of Clinical Oncology. 2025-04-01
CRE25-035: Vascular Endothelial Growth Factor Inhibitor-Induced Radiation Recall Tracheitis in a CASTLE Carcinoma of the Thyroid Patient.
Sahithee Alekhya Batchu, Yue Ma, Sue Yom, Chase Heaton, Alain Algazi
Journal of the National Comprehensive Cancer Network. 2025-03-28
1 citations
Neutrophil-to-Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma.
Angeline A Truong, Rex H Lee, Xin Wu, Alain P Algazi, Hyunseok Kang
Otolaryngology--Head and Neck Surgery. 2025-02-01

Journal Articles

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Kim Margolin, Alain Algazi, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igo..., The New England Journal of Medicine

Press Mentions

Leaving Lymph Nodes Intact Could Increase Efficacy of Cancer ImmunotherapyApril 12th, 2023
Sequential-Combinatorial Regimens Can Make Treatment More Effective for People with Aggressive CancersAugust 12th, 2021
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and NeckMay 19th, 2021
Join now to see all